Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
iSPERSE uses proprietary cationic salt formulations to create a robust and flexible platform that can accommodate high drug loads and large drug molecules in highly dispersible particles, yielding superior drug delivery capabilities compared to conventional dry powder technologies that rely on the use of lactose blending or low-density particles. The properties of iSPERSE have meaningful therapeutic and patient benefits, including single formulations with multiple drugs, effective inhaled drug delivery to patients with normal or impaired lung function, and the use of simple and convenient inhaler devices with highly reproducible dosing. Pulmonary drug delivery offers several advantages for both local and systemic applications. Drug delivery via inhalation for local applications results in direct targeting to the site of action and minimization of systemic exposure and side effects. The advantages of pulmonary drug delivery for systemic applications can include: rapid onset of action, avoidance of first pass metabolism, and elimination of injection.
iSPERSE powders are made via a straightforward, proven one- step spray drying process with high and consistent yields. A strong IP position on iSPERSE is being pursued through multiple patent applications, encompassing compositions, methods, and uses.
? Video demonstration of how iSPERSE works
PUR3100 is engineered with iSPERSE™ to address the ongoing need for an acute treatment of migraine
PUR3100 is currently in pre-clinical investigation as an orally inhaled migraine therapy; Phase 1a and Phase 1b data anticipated in 2022
Pulmazole™ is the first inhaled antifungal candidate designed to overcome the limitations of oral antifungals and also potentially reduce steroid burden. It is currently in a Phase 2 trial forthe treatment of ABPA in patients with asthma.
Pulmatrix and Cipla intend to initiate a Phase 2b study designed with a longer treatment duration and key phase 3 enabling efficacy endpoints when the potential risk to both patient safety and to patient enrollment, presented by the ongoing COVID-19 pandemic, is reduced to an acceptable level for patients with this serious respiratory condition.
Cipla is India’s 2nd largest pharmaceutical company with global presence in over 130 countries, over 35 manufacturing facilities, and a vast network for direct commercialization and strategic alliances.
PUR1800 is a Narrow Spectrum Kinase Inhibitor (NSKI) engineered with iSPERSE™ that is currently being investigated for the treatment of lung cancer. PUR1800 targets p38 MAP kinases (p38MAPK), Src kinases, and Syk kinases.17 These kinases play a critical role in chronicinflammation and airway remodeling.
"We look forward to 2021 as we plan to progress all of our programs. PUR1800 is planned to begin a clinical trial in early 2021, moving us closer to a potential licensing agreement with J&J for development and commercialization in lung cancer". From this article.
Johnson & Johnson is the world’s largest healthcare company with over 130,000 employees and 130 years of existence.
As you can see, their pipeline is quite impressive. What's even more impressive is the capability of this company to ink such big partnership deals with the biggest Pharma-giants in the sector. Remember this is a pennystock, so it's a huge confidence boost to see such interest in it. They also have an extremely solid management, of course, which I'm gonna link here: https://www.pulmatrix.com/leadership-management.html . Take a look at the Board of Directors: these guys are already in the game, leading other biopharma companies such as Kala Pharmaceuticals, Arena Pharmaceuticals. Nocion Therapeutics! https://www.pulmatrix.com/leadership-advisors.html
Pulmatrix recently had a DIRECT OFFERING https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html **"**P. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 20,000,000 shares of the Company's common stock, at a purchase price of $2.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions."
So yeah it's already closed, it was priced AT THE MARKET, it was a direct offering so institutions got in at 2$. No brainer right? At the current price, you have the chance to get in for a better one. But you know what's even more interesting? The offering was made for "healthcare-focused institutional investors"! This is the same bullish sign that I saw when Senseonics had its offering, seeing the interest in this company by healthcare experts made me add on the offering dips.
After this offering, they will have more than 70m in cash. They also receive royalties from partner Sensory Cloud upon sales of FEND, an OTC nasal hygiene product proven to reduce airborne respiratory droplets.
Check out their Q3 results, very promising and I'm looking forward for the Q4 ER https://finance.yahoo.com/news/pulmatrix-reports-third-quarter-2020-140000164.html
"As of September 30, 2020, Pulmatrix had $34.5 million in cash compared to $23.4 million as of December 31, 2019. Pulmatrix generated $4.4 million of revenue in the third quarter of 2020, compared to $1.4 million in the third quarter of 2019. The revenue for the second quarter of 2020 was the result of the collaboration and licensing agreements with Cipla and JJEI, respectively. Research and development expenses for the third quarter of 2020 and 2019 were $3.9 million and $3.3 million, respectively. Included in the third quarter 2020 costs were pre-clinical toxicology and Chemistry, Manufacturing and Controls costs for the PUR1800 program and clinical study costs incurred for the Phase 2 Pulmazole study. General and administrative expenses for the third quarter of 2020 and 2019 were $1.8 million. Included in the third quarter 2020 costs were general operating expenses such as employment, lab and office lease, legal, patent and audit fees. Net loss was $10.6 million for the third quarter of 2020 and $3.6 million for the third quarter of 2019. The net loss for the third quarter 2020 was primarily due to warrant inducement expense of $9.3 million and manufacturing costs for the upcoming PUR1800 Phase 1b clinical study and the recently terminated Pulmazole Phase 2 study. The net loss for the third quarter of 2019 was due to spend on the Pulmazole Phase 2 study."
About institutional ownership: https://fintel.io/so/us/pulm Go onto the website, you'll see that in the last weeks institutions piled in, from Vanguard to BlackRock to Renaissance Technologies.
There's currently a BUY rating and a 10$ price target, at least from what I've gathered online looking through various sources. We should probably expect news soon.